Key terms
About MREO
Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest MREO news
May 01
6:21am ET
Analysts Offer Insights on Healthcare Companies: Daré Bioscience (DARE), Mereo Biopharma Group Plc (MREO) and Arcus Biosciences (RCUS)
May 01
6:21am ET
Strong Buy Rating for Mereo Biopharma on Setrusumab’s Promising Phase 3 Progress and Financial Outlook
Apr 26
11:02am ET
Cantor Fitzgerald healthcare analysts hold an analyst/industry conference call
Mar 28
6:30am ET
Analysts Offer Insights on Healthcare Companies: Santhera Pharmaceuticals Holding (OtherSPHDF), Nuvation Bio (NUVB) and Mereo Biopharma Group Plc (MREO)
No recent press releases are available for MREO
MREO Financials
Key terms
Ad Feedback
MREO Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
MREO Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range